NCT02787369 2026-01-07ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLLDana-Farber Cancer InstitutePhase 1 Active not recruiting3 enrolled
NCT02091063 2024-08-06ACY-1215 for Relapsed/Refractory Lymphoid MalignanciesColumbia UniversityPhase 1/2 Terminated23 enrolled 6 charts